CDK12 Loss a Biomarker for Prostate Cancer Response to Immunotherapy?

DNA and RNA sequencing results suggest prostate cancer treatment “involving inhibition of CDK12 and immune checkpoint blockade,” a U Michigan team said.

Source: CancerNetwork - June 29, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Source Type: news